Andy Maitland is operations and supply chain director, Catalent.

Andy Maitland 

Micronization is an important tool for developing new drugs, its primary advantage being that it is scalable from the early stages of development through to commercial volumes. The micronization process is both well-understood and cost-effective.

With the increased number of potent drugs in development, having the capabilities to handle and process them is becoming imperative. Development partners with the specialized expertise and infrastructure required to handle potent APIs play a key role in the supply chain of next generation medicines.

Pharmaceutical Technology’s October 2021 APIs, Excipients, and Manufacturing eBook

Read the article:
Containing and Enhancing Potent Particles with Micronization

When referring to this article, please cite it as A. Maitland, “Containing and Enhancing Potent Particles with Micronization,” 

Pharmaceutical Technology APIs, Excipients, and Manufacturing 

Articles

A multilayered processing approach ensures safe handling and content uniformity of highly potent APIs.